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Prolactin (PRL) secreting pituitary adenomas are the most common type of pituitary tumors. An imaging 
agent which specifically localized in prolactinomas would be of considerable clinical value for both initial 
detection and also for monitoring the effects of dopamine agonist therapy. Tritiated spiroperidol ( 3HSp) 
was selected for initial evaluation as a possible imaging agent based on: (1) demonstrated localization in 
the pituitary and (2) demonstrated binding to human PRL-secreting tumor tissue. DES was implanted 
in Fischer F344 rats and induced prolactinoma formation was evidenced by increased pituitary weight, 
elevated serum PRL levels and by an increase in the proportion of PRL-secreting cells in the pituitary. 
‘HSp concentrations in pituitary and other tissues of DES-treated rats were assessed in female rats and 
correlation studies showed that a S-fold increase in serum PRL was associated with a 6-fold increase in 
both pituitary weight and % dose/organ accumulation of ‘HSp. The number of pituitary D, receptors 
per mg of protein in tissue homogenates was similar in both normal and DES-treated females. A blocking 
study with (+)-butaclamol demonstrated a D, receptor-mediated component to 3HSp localization. In 
summary, an animal model for prolactinoma was characterized. An assessment of ‘HSp accumulation 
indicates that radiolabelled spiroperidol shows excellent potential for detecting PRL-secreting tumors of 
the pituitary. 
Introduction 
Prolactin (PRL) secreting pituitary adenomas are the 
most common type of pituitary tumors. The high 
incidence of these tumors only became apparent 
within the past 9-10 years as a result of the devel- 
opment and general availability of a radio- 
immunoassay for measurement of PRL in serum.(‘,2) 
These tumors are common in females who usually 
present with galactorrhea, amenorrhea or infertility 
although other local effects such as visual dis- 
turbances from compression of the optic chiasma 
may be evident. It is now recognized that approxi- 
mately 2&25% of all women with amenorrhea have 
prolactinomas.(3s4) 
The detection of prolactinomas currently depends 
on physical symptoms, elevated serum PRL levels 
and abnormal CT scans of the sella turcica. However, 
other disorders such as pituitary cysts may present 
* Author for correspondence. 
with both elevated serum PRL and abnormal CT 
scans.(‘) Not only have surgically confirmed pro- 
lactinomas been found in patients with normal CT 
scans and with elevated serum PRL,(“8) but abnormal 
CT scans have a predictive value of only 22% for 
pituitary tumors in patients with no clinical history of 
pituitary disease.(g) CT scans do not functionally 
characterize tumors but merely indicate density 
changes which are presumed to reflect the presence of 
a tumor. Thus, diagnosis may be imprecise and often 
rests on the association of an elevated serum PRL 
level with a possible CT scan abnormality. 
Prolactinomas have been demonstrated using 
~mTc]pertechnetate.(‘o~“) However, PgmTc]pertech- 
netate does not functionally characterize tumors but 
reflects increased vascularization and vascular perme- 
ability associated with tumor presence. Nuclear mag- 
netic resonance (MR) has recently been evaluated for 
pituitary tumor imaging(12,‘3) but MR also does not 
functionally characterize tumor type. 
Thus, an imaging agent which specifically localizes 
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in prolactinomas based on some functional character- 
istic of the tumor would be of considerable clinical 
value. Positive imaging of these tumors would enable 
a definite diagnosis of PRL-secreting adenoma to be 
made and this would represent an improvement over 
existing CT scans. Earlier detection may be possible 
and the effects of medical therapy (e.g. bromo- 
criptine) on functional status and tumor size could be 
monitored in a serial manner. 
Prolactin secretion appears to be largely under 
dopamine control. Dopamine, which is secreted into 
the hypophyseal portal blood, may inhibit PRL 
secretion by binding to receptors in the pituitary.(‘4) 
The anterior pituitary is thought to contain exclu- 
sively postsynaptic D, receptors.(i5.i6) Studies indicate 
that most human prolactinomas have intact dop- 
amine receptor sites on the PRL-producing cells.“’ 19’ 
There are contrasting reports regarding the numbers 
of receptor sites in human prolactinomas. One study 
by Cronin et al. using spiroperidol found increased 
numbers of binding sites”“) while Bression and col- 
leagues using ‘H-domperidone report decreased num- 
bers.“9’ Further quantification studies using a uni- 
form receptor concentration assay are necessary to 
clarify this point. Regardless, the increase in PRL- 
secreting cells (mammotrophs) in prolactinomas cou- 
pled with the presence of dopamine receptors capable 
of binding 3H-neuroleptics(‘5) raises the possibility of 
receptor-mediated imaging of these tumors with a 
radiolabelled Dz receptor antagonist. 
Development of a suitable imaging agent depends 
not only on the synthesis of an appropriate radio- 
pharmaceutical but on the availability of an animal 
tumor model with characteristics similar to human 
prolactinomas. A recent publication has shown that 
implantation of diethylstilbestrol (DES) in Fischer 
F344 rats resulted in the induction of PRL-secreting 
hyperplasia/tumor of pituitary tissue in almost all 
animals within 8-12 weeks after implantation.(20) 
Treatment with estradiol had no effect on the affinity 
of the dopamine receptor for spiroperidol’*” but the 
effect of estrogens on the number of dopamine recep- 
tors in the rat pituitary is uncertain and has been 
reported to remain constant’*‘) or to be reduced by 
approximately 50%. (22) The presence of functioning 
pituitary dopamine receptors together with elevated 
serum PRL levels suggests that the DES-treated F344 
rat is a suitable animal model for the assessment of 
potential imaging agents for prolactinomas. 
As we have previously reported on the uptake of 
‘HSp in the normal pituitary of Fischer F344 rats(23i 
and as ‘HSp binding to human PRL-secreting tumor 
tissue has been demonstrated,“*) we evaluated ‘HSp 
in the DES-induced prolactinoma mode1 rats. The 
concentration and retention of spiroperidol or 
its analogs in any pituitary tumor have not been 
determined. 
Thus, we have studied (I) the time course of ‘HSp 
activity in tissues of DES-treated female F344 rats, 
(2) the effect of (+)-butaclamol on ‘HSp pituitary 
concentration, (3) the number of Dz receptors in 
normal and DES-treated female rat pituitary, and (4) 
the correlations between ‘HSp concentration in the 
pituitary, serum prolactin levels and percent and 
number of PRL-producing cells in pituitary tissue of 
male and female rats treated with DES. 
Materials and Methods 
The following compounds or reagents were ob- 
tained from commercial sources: 3H-spiroperidol 
(25-30 Ci/mmol) (New England Nuclear), diethyl- 
stilbestrol (Aldrich Chemical Co.) avidin-biotin 
peroxidase complex (Vector Laboratory), diamino- 
benzidine hydrochloride, pargyline (Sigma Chemical 
Co.) (+)-butaclamol hydrochloride (Research Bio- 
chemicals Inc.). Dow Corning Silastic tubing and 
silicone adhesive type A were obtained commercially, 
as were the scintillation fluids used in counting, 
Ox-triti-stint (Romac) for tissue samples and ACS 
(Amersham) for binding assays. 
Polyclonal antiserum to rat prolactin was obtained 
from the NIADDK. The NIADDK Pituitary Hor- 
mone Distribution Program supplied materials and 
protocols for the double antibody RIA for rat 
prolactin. 
Fischer F344 rats, male and female, were pur- 
chased (Charles River). Animals were exposed to 
alternating 12 h periods of light and dark and re- 
ceived rat chow and water ad libitum during the 
study. 
Tumor model 
Prolactin secreting adenomas were induced by 
implanting DES-containing Silastic tubing S.C. into 
30 day old rats under ether anesthesia through a 
small incision in the back.‘*‘) Control rats were im- 
planted with empty Silastic tubing. The DES- 
implants were prepared as described except that 3/4 
in. lengths of tubing were used and these were filled 
with 10mg of DES. Both blank and DES-implants 
were soaked in 2% BSA solution for 24 h prior to 
implanting in the rats. 
Immunohistochemical staining 
The anterior and posterior pituitary lobes were 
removed separately and the anterior pituitary fixed in 
3 mL of 10% formalin for 24 h at 23°C before being 
embedded in paraffin. Tissue sections were cut sagit- 
tally with a microtome (5 pm) and stained with 
hematoxylin and eosin. Other sections were stained 
for PRL by immunohistochemical methods.‘“) After 
inhibiting endogenous peroxidase with 1% 
methanol-H,O, tissues were washed in phosphate 
buffered saline (PBS), then treated with normal goat 
serum to suppress nonspecific binding for 30 min. Rat 
anti-PRL serum (produced in rabbits and used at 
1: 1000 dilution) was applied for 1 h at 23°C. The 
tissues were washed with PBS treated with 1:200 
dilution of rabbit biotin-IgG made in goat for 30 min, 
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followed by PBS washes, then incubation with 
avidin-biotin peroxidase complex for 30 min. Di- 
aminobenzidine (DAB) was used as the chromogen 
(10 mg DAB in 50 mL PBS, pH 7.2 and 0.001% 
H,O,) for 5min. 
Controls consisted of substituting normal rabbit 
serum for the primary antibody and absorbing each 
antibody with specific antigens for 24 h before per- 
forming the assay. Additional controls consisted of 
omitting biotin-IgG or avidin-biotin peroxidase 
complex. All of these controls resulted in no staining 
of the tissues. The number of cells staining positively 
for PRL was counted by systematically sampling the 
entire pituitary tissue using a 4mm2 grid in the 
microscope ocular. A minimum of 1000 cells per slide 
were counted and scored as negative or positive if a 
brown-black reaction product was present in the 
cytoplasm. 
Serum prolactin assay 
Serum PRL was determined for all rats, male and 
female, control and DES-treated, using a published 
radioimmunoassay procedure.(25) 
D, receptor binding assay 
Female Fischer F344 rats under ether anesthesia 
were killed by decapitation. Normals were 8 weeks of 
age; DES-treated were sacrificed 4 weeks after im- 
plant. The pituitaries were rapidly removed and 
washed free of blood in cold saline. The anterior 
lobes were separated and stored at -70°C until 
assayed. Pituitaries from both normal and DES- 
treated rats were assayed simultaneously. Tissue sam- 
ples were homogenized at low speed with a Tekmar 
homogenizer using 30 vol of cold buffer (0.25 M 
sucrose, 15 mM Tris, 120 mM NaCl, 5 mM KCI, 
2 mM CaCl,, 1 mM MgQ, 0.1 mM EDTA,(32) 2 PM 
pargyline, 0.1% ascorbate, pH 7.4, 25°C). The ho- 
mogenate was centrifuged twice as described.(2’) The 
final pellets were resuspended in Tris buffer (as above 
but omitting sucrose) and incubated for 10 min at 
37°C. The homogenates were then assayed for pro- 
tein contentt2@ and diluted with buffer to a final 
concentration of about 0.2 mg protein/100 pL. 
For binding studies, 600 p L samples were prepared 
in triplicate as described by Cronin and Weiner.(27) 
Assays contained about 0.2mg protein. Membrane 
bound ‘HSp was separated by rapid filtration (< 5 s) 
under vacuum over Schleicher & Schuell No. 34 glass 
fiber filters and washed with 3 x 4mL cold Tris 
buffer. The filters were placed in scintillation vials 
and 3 mL scintillation fluid added. The samples were 
stored until translucent, then counted. All values 
were corrected for background. 
Specific binding was defined as the total counts of 
‘HSp minus the counts obtained in the presence of 
lOOO-fold excess of (+)-butaclamol (pharmacolo- 
gically active form). Scatchard analysis was per- 
formed to determine the apparent dissociation 
constant K,, and the maximal number of receptor 
sites, B,,,, for both normal and DES-treated 
pituitary. 
Tissue distribution studies 
DES-treated. Female Fischer F344 rats were im- 
planted with DES as described above and sacrificed 
4 weeks later. Tissue distribution studies were per- 
formed as described(23) at 5 min and at 1 and 2 h post 
injection. 
(+)-Butaclamol treated. Female rats implanted 
with DES were treated with (+)-butaclamol 
(2 mg/kg, n = 6, and 5 mg/kg, n = 6) 45 min prior to 
‘HSp injection (25 PCi). Tissue distribution studies 
were performed as described at t = 1 h post ‘HSp 
injection. 
Correlation studies 
Protocol. Correlation studies were similarly per- 
formed on male and female rats. Thirty day old 
Fischer F344 rats (12 per group for each time period 
of 4 and 8 weeks) were implanted with blanks or 
DES. After 4 weeks for female rats, and after 4 and 
8 weeks for male rats, the animals were separated into 
two groups of six animals and treated as follows. All 
animals were killed by decapitation, pituitaries re- 
moved and blood collected. Serum was kept frozen 
until use for PRL assay. The uteri of all female rats 
were removed, cleaned of fat, connective tissue and 
excess fluid and weighed. Six were treated as de- 
scribed above for tissue distribution studies. Six 
pituitaries were fixed for determination of the per- 
centage of PRL-producing cells by immuno- 
histochemical staining. 
Results 
Effects of DES treatment 
The effects of DES on uterine and pituitary weight 
were determined. Uterine weight was 320 f 60 mg for 
10 mg DES implanted for 4 weeks. This is compara- 
ble to 250 mg reported for 4 weeks of treatment with 
5mg DES c20) As expected, pituitary weights also 
increased and are presented in Table 3. For both 
males and females, the 1Omg dosage of DES used 
resulted in higher pituitary weights than reported 
after 5 mg DES treatment.‘20) 
The induction of PRL-secreting tumor was verified 
by the increase in weight of the anterior pituitary, by 
the elevation of serum PRL levels and by an increase 
in the numbers of PRL-secreting cells. In both male 
and female rats, the increase in PRL-secreting cells 
was uniformly distributed in the anterior pituitary. 
Figures 1A and B are examples of pituitary tissue 
from normal and DES-treated female rats after im- 
munohistochemical staining. 
Time course in DES-treated rats 
The concentration data of ‘H-activity in various 
tissues from DES-treated rats is compiled in Table 1. 
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Anterior pituitary 0.29’ f 0.046 0.321 k 0.014 0.224 + 0.035 
Posterior pituitary _c 0.220 * 0.053 0.097 f 0.029 
uterus 0.144+-0.017 0.123 i 0.003 0.131 +0.016 
Blood 0.026 k 0.004 0.0 I7 f 0.002 0.021 * 0.005 
an = 3, Fischer F344 rats sacrificed 4 weeks after IO mg DES implant. 
bData as % kg dose/g, mean f SEM. 
CPosterior pituitary not adequately distinguishable from anterior pituitary for two 
of the rats. 
Over a time span from 5 min to 2 h, the concentration 
in anterior and posterior pituitary, uterus and blood 
was approximately constant for both normal (data 
from Ref. 23) and DES-treated female rats. In DES- 
treated animals, anterior pituitary values were ap- 
proximately 10 times that seen in other tissues. 
The posterior pituitary could usually be visually 
distinguished from the anterior pituitary at 4 weeks 
after DES treatment in female rats. However, in 
female rats implanted with 10 mg DES and sacrificed 
8 weeks later, the tumors of all rats (n = 9) appeared 
necrotic and hemorrhagic. Concentration data in 
such tumors is of questionable validity so further 
evaluation was not performed. The posterior pituit- 
ary could not be distinguished from anterior pituitary 
in these rats. 
Butaclamol blocking study 
DES-treated female rats were pretreated with two 
dosages of (+)-butaclamol-2 and 5 mg/kg. Results 
were similar for all tissues examined at both dosage 
levels and only percent kg dose/g values for 2 mg/kg 
are presented in Table 2. 
D, receptor binding assay 
Scatchard analysis of ‘HSp specific binding to 
Table 2. ‘H-spiroperidol activity for (+)-butaclamol treated rats 






% kg dose/g 
0.232 + 0.014 
0.238 k 0.055 
0.079 * 0.002 
0.016 +O.OOl 
% Reduction’ 
28 f 7 
36 k 4 
VI = 6, Fischer F344 rats implanted with IO mg DES. Rats injected 
with (+)-butaclamol (2 mg/kg) 45 min prior to ‘HSp injection 
(25 PCi). Sacrifice at I = I h post ‘HSp injection. 
“Data as % kg dose/g, mean + SEM. 
‘Percent relative to % kg dose/g at I = 1 h for DES-treated rats 
(data in Table I). Only statistical differences are listed. 
anterior pituitary homogenates from normal and 
DES-treated female rats was performed. The appar- 
ent K, is 0.15 + 0.06 nM for normals and 0.19 + 0.08 
for DES-treated animals. The maximum number of 
D, receptor sites (B,,,,,) was also similar for normal 
(71 f 13 fmol/mg protein) and DES-treated rats 
(63 + 11). 
Correlation studies 
The relationship between serum PRL levels and the 
percent of PRL-secreting cells present in control and 
DES-implanted male and female rats is presented in 
Table 3. The increase in serum PRL levels to 
Table 3. Correlation between serum prolactin levels, anterior pituitary weights, percent prolactin secreting cells and 
‘H-spiroperidol concentration at I = I h post injection” 
Male Female 







4wk 93+ 10 1170* II0 506 f 139 2500 f 199 
8wk 180+27 3600 * 340 
4wk 5.18 f 0.37 21.1 * 3.0 5.41 f 0.75 33.81 f 2.80 
8wk 5.26 _+ 0.3b 107 f I7 
4wk 14.4 * 1.4 35.7 f 2.2 32.3 k I .4 79.7 f I .o 
8wk 15.2 f O.Sd 46.4 f I .Sd 










4wk 0.219 f 0.013 0.3 17 i 0.008 0.363 5 0.022 0.311 kO.140 
4wk 0.081 + 0.030d 0.182~0.012 0.254 i 0.038 0.220 * 0.053 
8wk 0.482 5 0.084b 0.278 + 0.014 
8wk 0.292 + 0.095b 
4wk 0.008 + 0.001 0.062 f 0.008 0.016 f 0.002 0.093 + 0.010 
4wk 0.002 + 0.000 0.003 rt 0.006 0.002 f 0.000 0.003 * 0.000 
8wk 0.01 I * O.OOlb 0.218 i 0.032 
8wk 0.002 f 0.000 
‘n = 6, Fischer F344 rats implanted at 30 days with 0.0 mg DES (control) and 10.0 mg DES, mean + SEM 
bn =3. 
‘Percent per minimum of 1000 cells counted. 
4” = 5. 
Fig 
;‘B: 
1. (A) Normal anterior pituitary gland horn a female rat stained for PRL by immunohistuchemistry. 
&k reaction product is present in the cytoplasm of PRL-producing cek (Immunoperoxidase x 330.) 
Pituitary gland from DES-treated female rat stained for PRL by inlmunohistochemistry. Most or the 
tumor cells contain immunoreactive PRL. (Immunoperoxidase x 330.) 
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1170 f 110 ng/mL for males and to 2500 k 199 for 
females was associated with a 2.5 fold increase in the 
percent of PRL-secreting cells in the anterior pitu- 
itary of both male and female rats at 4 weeks. When 
placed in conjunction with increasing pituitary 
weight, this increase in percent of PRL-secreting cells 
corresponds to a 10 fold increase in the total number 
of PRL-secreting cells for males and a 15 fold in- 
crease for females. Male rats were also evaluated at 
8 weeks as the pituitary tumors, in contrast to females 
at 8 weeks, were smaller, less vascularized and did not 
appear hemorrhagic (see Time course in DES-treated 
rats above). 
The tissue cona:ntrations of 3H-spiroperido1 are 
also presented in l’able 3. Concentration values are 
presented as % kg dose/g, the normalized tissue 
concentration, and as % dose/organ which reflects 
the fraction of the dose administered which localized 
in the anterior pituitary. In male rats a 10 fold 
increase in serum PRL level is associated with an 8 
fold increase in the % dose/organ and a 4 fold 
increase in anterior pituitary weight. In female rats a 
5 fold increase in serum PRL is associated with a 6 
fold increase in % dose/organ and a 6 fold increase 
in anterior pituitary weight. Figure 2 shows the 
correlation between % dose/organ and serum PRL 
levels in male and female rats in graphic form. 
The correlation between percent PRL cells with % 
dose/organ and % kg dose/g is also contained in 
Table 3. Percent dose/organ values in the posterior 
pituitary are minimally affected by treatment with 
DES (less than 2 fold increase) and are the same for 
male and female rats at all time intervals. Anterior 
pituitary values increased dramatically, as stated 
above. In sharp contrast to % dose/organ increases, 
the % kg dose/g values relative to control values 
remained approximately constant for males and 
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females at 4 weeks and showed a 50% decrease in 
males at 8 weeks. It is interesting that the 6 fold 
increase in % dose/organ for females and the 8 fold 
increase for males correlate with a 2.5 fold increase 
in the percent of PRL-producing cells for both female 
and male rats. 
Discussion 
Time course in DES-treated rats 
The dissociation constants of 3HSp from human 
anterior pituitary and from human PRL-secreting 
pituitary adenomas are similar [K,, = 2.2 & 0.7 and 
3.1 + 1.4 nM, respectively (mean f SEM(“‘]. The 
similarity in KD suggests that the time course for 
3HSp uptake by tumor tissue may be the same as in 
normal tissue. Comparison of data in Table 1 with 
data from normal rats (See Table 1 in Ref. 23) shows 
that ‘HSp uptake appears to be constant from 5 min 
to 2 h in both normal and tumor pituitary tissue. 
Percent kg dose/g in anterior pituitary is a normalized 
value and reflects concentration of injected 
radioactivity/g tissue. The data suggest that although 
the pituitary weight has increased 6 fold due to 
tumor, the concentration/g tissue has remained ap- 
proximately constant. Because of the similarity in 
data between normal and DES-tumor induced rats, 
further time intervals were not evaluated. 
Butaciamol blocking study 
As with the time course results, the data obtained 
from rats pretreated with butaclamol are experi- 
mentally equivalent for both contro1(23) and DES- 
induced tumor bearing rats. That is, the 28 + 7% 
reduction observed in anterior pituitary is lower than 
that reported for cortex and striatum. The reduction 
> 0.3 - 
(L l Male,4wk control 
J \ Mole,4 wk DES 
5 
if 
_ 0 Mole,6 wk control 
Q Mole,8 wk DES 
8 
0 Female,4 wk control 
ti 0.2 - 




SERUM PROLACTIN LEVEL (ng/mll 
Fig. 2. Percent dose/organ vs serum prolactin level in male and female rats after treatment with DES and 
in controls. Sacrifice was at 1 h post injection. (Correlation factor r = 0.9987.) 
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in ‘HSp uptake is supportive that some concentration 
of ‘HSp is due to D, receptor specific binding. 
D, receptor binding assay 
The KD value observed for normal rats is similar to 
that reported using F344 male anterior pituitary, 
0.10 f 0.04 nM(28’ and other rat anterior pituitary 
tissue.(29 32) Likewise the apparent Kd for DES-treated 
pituitary is comparable to values reported for es- 
tradiol treated adult male F344 rats: 0.12 k 0.02 and 
0.15 k 0.03 nM for 15 and 90 days of estradiol treat- 
ment, respectively.(28) 
The &,, values reported here are similar to those 
reported for male F344 rats.(28) These data suggest 
that DES treatment did not significantly alter the 
observed B,,,,, which is in agreement with data ob- 
tained using estrogen treated adult male F344 rats(28) 
and adult female Sprague-Dawley rats,(2’,32) and con- 
trasts with data obtained from female Wistar rats.c2’) 
B,,,,, determination is in terms of mg pituitary protein 
and does not include any correction for the percent 
of PRL-secreting cells (see following discussion). 
Correlation study 
When % dose/mg pituitary is calculated by 
dividing % dose/organ by anterior pituitary weight 
(data in Table 3), the value is 0.0024 f0.0005% 
dose/mg and is independent of sex or length of DES 
treatment. This similarity suggests that, although 
pituitary weight increased, the relative uptake/mg 
tissue has remained constant. If one assumes that 
3HSp localization in the pituitary is dependent on at 
least an initial complex formation with the D, recep- 
tor, then one might expect that the concentration of 
D, receptors/mg tissue has also remained constant. 
Data presented earlier in D, receptor assay show that 
the concentration of D, receptors in DES induced rat 
prolactinoma is approximately the same as in con- 
trols. Consideration of the D, receptor concentration 
in connection with the (for females) 15 fold increase 
in the number of PRL-secreting cells suggests that the 
number of D, receptors per PRL-secreting cell has 
been reduced. The relationship between increases in 
% dose/organ and increases in the number of PRL- 
secreting cells may also be interpreted as support for 
reduction of number of D, receptors per cell. For 
males, the number of PRL cells increase about 1.3 
times faster than % dose/organ; for females, this rate 
of increase is about 2.7. Although the relationship 
differs for males and females, apparently uptake as % 
dose/organ is not directly correlated with increasing 
number of PRL cells. 
In general terms, for both male and female rats at 
4 weeks, increasing serum PRL levels were accom- 
panied by increases in the percent and number of 
PRL-secreting cells and by increases in pituitary size. 
These increases correlate with increasing % 
dose/organ values. For males and females, there 
appear to be different rates of increase of % 
dose/organ (8 fold for males, 6 fold for females), 
serum PRL (12 fold for males, 5 fold for females), 
and number of PRL-secreting cells (10 fold vs 15 
fold). 
Prolactinoma imaging assessment 
The goal of the present work was to develop an 
animal model that could be used to screen radio- 
tracers for their potential as mammotroph (pro- 
lactinoma) imaging agents. Based on the observed 
uptake in rats in DES induced prolactinomas and in 
normal tissue, radiolabelled spiroperidol shows excel- 
lent potential for detecting both PRL-secreting pitu- 
itary tumors and normal pituitary. Since the size of 
the pituitary in humans is at the resolution limit of 
various brain imaging instruments, early presence of 
a prolactinoma would need to be inferred from an 
uptake measurement which could best be performed 
using single photon tomography. In the DES- 
stimulated pituitary, both pituitary mass and density 
of PRL-secreting cells increased with the net effect of 
increasing the uptake per organ by a factor ranging 
from a low of 5.8 for female rats at 4 weeks to a high 
of 19.8 for males at 8 weeks. It is highly likely that 
increases of this magnitude will lie well outside the 
normal variation for humans and could be detected 
even at count rates ranging from 12 to 70cpm 
predicted in a worst case analysis of a hypothetical 
normal pituitary. (23) Since the pituitary is below the 
brain and since it is surrounded by bone, imaging the 
pituitary will be similar to imaging a point source in 
background. One can therefore expect good results in 
uptake measurements. 
Future efforts will use this model and a series of 
other radiolabelled D, agonists and antagonists. In 
other studies, attempts will be made to induce pitu- 
itary adenomas in larger animals to permit direct 
scintigraphy evaluations. 
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